Synaptogenix (NASDAQ:TAOX – Get Free Report) and Endonovo Therapeutics (OTCMKTS:ENDVD – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Risk and Volatility
Synaptogenix has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.
Profitability
This table compares Synaptogenix and Endonovo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synaptogenix | N/A | -240.92% | -150.03% |
| Endonovo Therapeutics | -6,075.54% | N/A | -279.35% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synaptogenix | 1 | 0 | 0 | 0 | 1.00 |
| Endonovo Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Given Endonovo Therapeutics’ higher probable upside, analysts clearly believe Endonovo Therapeutics is more favorable than Synaptogenix.
Earnings and Valuation
This table compares Synaptogenix and Endonovo Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synaptogenix | N/A | N/A | -$12.77 million | ($20.16) | -0.19 |
| Endonovo Therapeutics | $170,000.00 | 0.00 | -$400,000.00 | ($10.00) | N/A |
Endonovo Therapeutics has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Endonovo Therapeutics beats Synaptogenix on 7 of the 12 factors compared between the two stocks.
About Synaptogenix
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
